Impaired social motivation and increased aggression in rats subchronically exposed to phencyclidine

Physiology and Behavior

Volumn 96, Issue 3, 2009, Pages 394-398

  Audet, Marie Claude ^a   Goulet, Sonia ^b,c   Doré, François Y ^b,c  

^a CARLETON UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

Aggression; Motivation; Phencyclidine; Schizophrenia; Social interaction

Indexed keywords

PHENCYCLIDINE; SODIUM CHLORIDE;

AGGRESSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; MALE; MOTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOCIOPATHY;

AGGRESSION; ANALYSIS OF VARIANCE; ANIMALS; AVOIDANCE LEARNING; DRUG ADMINISTRATION SCHEDULE; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; MALE; MOTIVATION; PHENCYCLIDINE; RATS; RATS, LONG-EVANS; SOCIAL BEHAVIOR;

EID: 58949090461     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2008.11.002     Document Type: Article

References (50)

1. Andreasen N.C., Flaum M., Swayze II V.W., Tyrrell G., and Arndt S. Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch Gen Psychiatry 47 7 (1990) 615-621
2. Andreasen N.C., and Flaum M. Schizophrenia: the characteristic symptoms. Schizophr Bull 17 1 (1991) 27-49
3. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148 10 (1991) 1301-1308
4. Done D.J., Crow T.J., Johnstone E.C., and Sacker A. Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. BMJ 309 6956 (1994) 699-703
5. Horan W.P., Subotnik K.L., Snyder K.S., and Nuechterlein K.H. Do recent-onset schizophrenia patients experience a "social network crisis"?. Psychiatry 69 2 (2006) 115-129
6. Cannon T.D., Cadenhead K., Cornblatt B., Woods S.W., Addington J., Walker E., et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 65 1 (2008) 28-37
7. Cornblatt B.A., Auther A.M., Niendam T., Smith C.W., Zinberg J., Bearden C.E., et al. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull 33 3 (2007) 688-702
8. Peralta V., and Cuesta M.J. Motor features in psychotic disorders. I. Factor structure and clinical correlates. Schizophr Res 47 2-3 (2001) 107-116
9. Seeman M.V. Symptoms of schizophrenia: normal adaptation to inability. Med Hypotheses 69 2 (2007) 253-257
10. Bozikas V.P., Kosmidis M.H., Anezoulaki D., Giannakou M., Andreou C., and Karavatos A. Impaired perception of affective prosody in schizophrenia. J Neuropsychiatry Clin Neurosci 18 1 (2006) 81-85
11. Kohler C.G., Turner T.H., Bilker W.B., Brensinger C.M., Siegel S.J., Kanes S.J., et al. Facial emotion recognition in schizophrenia: intensity effects and error pattern. Am J Psychiatry 160 10 (2003) 1768-1774
12. Kosmidis M.H., Bozikas V.P., Giannakou M., Anezoulaki D., Fantie B.D., and Karavatos A. Impaired emotion perception in schizophrenia: a differential deficit. Psychiatry Res 149 1-3 (2007) 279-284
13. Turetsky B.I., Kohler C.G., Indersmitten T., Bhati M.T., Charbonnier D., and Gur R.C. Facial emotion recognition in schizophrenia: when and why does it go awry?. Schizophr Res 94 1-3 (2007) 253-263
14. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 3 (1999) 201-225
15. Moghaddam B., and Jackson M.E. Glutamatergic animal models of schizophrenia. Ann NY Acad Sci 1003 (2003) 131-137
16. Morris B.J., Cochran S.M., and Pratt J.A. PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 5 1 (2005) 101-106
17. Boulay D., Depoortère R., Louis C., Perrault G., Griebel G., and Soubrié P. SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. Neuropharmacology 46 8 (2004) 1121-1129
18. Bruins Slot L.A., Kleven M.S., and Newman-Tancredi A. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 49 7 (2005) 996-1006
19. Sams-Dodd F. Automation of the social interaction test by a video-tracking system: behavioural effects of repeated phencyclidine treatment. J Neurosci Methods 59 2 (1995) 157-167
20. Sams-Dodd F. A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. Neuropsychopharmacology 18 4 (1998) 293-304
21. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible model for schizophrenia. Behav Pharmacol 7 1 (1996) 3-23
22. Tanaka K., Suzuki M., Sumiyoshi T., Murata M., Tsunoda M., and Kurachi M. Subchronic phencyclidine administration alters central vasopressin receptor binding and social interaction in the rat. Brain Res 992 2 (2003) 239-245
23. Qiao H., Noda Y., Kamei H., Nagai T., Furukawa H., Miura H., et al. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 12 1 (2001) 11-15
24. Sams-Dodd F. (+) MK-801 and phencyclidine induced neurotoxicity do not cause enduring behaviours resembling the positive and negative symptoms of schizophrenia in the rat. Basic Clin Pharmacol Toxicol 95 5 (2004) 241-246
25. Lee P.R., Brady D.L., Shapiro R.A., Dorsa D.M., and Koenig J.I. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 30 10 (2005) 1883-1894
26. Genn R.F., Tucci S.A., Thomas A., Edwards J.E., and File S.E. Age-associated sex differences in response to food deprivation on two animal tests of anxiety. Neurosci Biobehav Rev 27 1-2 (2003) 155-161
27. Audet M.C., Goulet S., and Doré F.Y. Repeated subchronic exposure to phencyclidine elicits excessive atypical grooming in rats. Behav Brain Res 167 1 (2006) 103-110
28. Audet M.C., Goulet S., and Doré F.Y. Transient hypolocomotion in rats repeatedly exposed to phencyclidine: an appraisal of motor function and motivation. Prog Neuropsychopharmacol Biol Psychiatry 31 1 (2007) 142-150
29. Jentsch J.D., Tran A., Le D., Youngren K.D., and Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependant cognition in the rat. Neuropsychopharmacology 17 2 (1997) 92-99
30. Marquis J.P., Audet M.C., Doré F.Y., and Goulet S. Delayed alternation performance following subchronic phencyclidine administration in rats depends on task parameters. Prog Neuropsychopharmacol Biol Psychiatry 31 5 (2007) 1108-1112
31. Noda Y., Yamada K., Furukawa H., and Nabeshima T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol 116 5 (1995) 2531-2537
32. File S.E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Methods 2 3 (1980) 219-238
33. Kappas A. Coder2 (1995), École de psychologie, Université Laval, Québec (Canada)
34. Cairns R.B., and Scholz S.D. Fighting in mice: dyadic escalation and what is learned. J Comp Physiol Psychol 85 3 (1973) 540-550
35. Gendreau P.L., Gariépy J.L., Petitto J.M., and Lewis M.H. D1 dopamine receptor mediation of social and nonsocial emotional reactivity in mice: effects of housing and strain difference in motor activity. Behav Neurosci 111 2 (1997) 424-434
36. Becker A., Peters B., Schroeder H., Mann T., Huether G., and Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Prog NeuroPsychopharmacol Biol Psychiatry 27 4 (2003) 687-700
37. Becker A., and Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. Prog NeuroPsychopharmacol Biol Psychiatry 28 8 (2004) 1267-1277
38. Green M.F., Olivier B., Crawley J.N., Penn D.L., and Silverstein S. Social cognition in schizophrenia: recommendations from the measurement and treatment research to improve cognition in schizophrenia new approaches conference. Schizophr Bull 31 4 (2005) 882-887
39. Lopez-Ibor J.J., Lopez-Ibor M.I., Mendez M.A., Moron M.D., Ortiz-Teran L., Fernandez A., et al. The perception of emotion-free faces in schizophrenia: a magneto-encephalography study. Schizophr Res 98 1-3 (2008) 278-286
40. Frith C.D. The cognitive neuropsychology of schizophrenia (1992), L.E.A. Publishers, Hillsdale, U.S.A
41. Cohen A.S., Forbes C.B., Mann M.C., and Blanchard J.J. Specific cognitive deficits and differential domains of social functioning impairment in schizophrenia. Schizophr Res 81 2-3 (2006) 227-238
42. Couture S.M., Penn D.L., and Roberts D.L. The functional significance of social cognition in schizophrenia: a review. Schizophr Bull 32 suppl.1 (2006) 44-63
43. Dickerson F., Boronow J.J., Ringel N., and Parente F. Neurocognitive deficits and social functioning in outpatients with schizophrenia. Schizophr Res 21 2 (1996) 75-83
44. Ledoux J. The emotional brain: the mysterious underspinning of emotional life (1996), Simon & Schuster, NY
45. Ledoux J. The amygdala. Curr Biol 17 20 (2007) R868-874
46. Morris R. Theories of hippocampal function. In: Andersen P., Morris R., Amaral D., Bliss T., and O'Keefe J. (Eds). The hippocampus book (2007), Oxford University Press, NY
47. Turgeon S.M., and Hoge S.G. Prior exposure to phencyclidine decreases voluntary sucrose consumption and operant performance for food reward. Pharmacol Biochem Behav 76 3-4 (2003) 393-400
48. Spielewoy C., and Markou A. Withdrawal from chronic phencyclidine treatment induces long-lasting depression in brain reward function. Neuropsychopharmacology 28 6 (2003) 1106-1116
49. Noda Y., Mamiya T., Furukawa H., and Nabeshima T. Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur J Pharmacol 324 2-3 (1997) 135-140
50. Noda Y., Kamei H., Mamiya T., Furukawa H., and Nabeshima T. Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 23 4 (2000) 375-387